Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
Conditions
- Lymphoma
- Relapsed Lymphoma
- Refractory Lymphoma
- Relapsed and/or Refractory Lymphoma
- Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)
- Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Double-hit Lymphoma (DHL)
- Triple-hit Lymphoma (THL)
- Double-expressor Lymphoma (DEL)
- High-grade B-cell Lymphoma (HGBL)
Interventions
- DRUG: fimepinostat
- DRUG: Rituximab
- DRUG: venetoclax
Sponsor
Curis, Inc.
Collaborators